Natco Pharma launches generic Carboplatin Injection in US

Natco Pharma launches generic Carboplatin Injection in US — Natco Pharma has announced the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market. This launch expands its presence in the competitive oncology generics segment. The product is approved by the USFDA and will be marketed by partner Sagent Pharmaceuticals. First-to-file status may offer 180-day marketing exclusivity, boosting near-term revenue potential.

📊 STOCKS: $NATCOPHARM | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #DrugLaunch